Immunoglobulins in neonates with rhesus hemolytic disease of the fetus and newborn: long-term outcome in a randomized trial
Fetal Diagnosis and Therapy 2016;39(3):209-213
van Klink JM, van Veen SJ, Smits-Wintjens VE, Lindenburg IT, Rijken M, Oepkes D, Lopriore E
co-author, author 4 of 7·doi·pubmed
Summary
Follow-up of the randomised trial of intravenous immunoglobulin in newborns with rhesus haemolytic disease. The children were assessed years later with standardised tests. Neurodevelopment did not differ between the immunoglobulin and placebo groups.
Summary based on the published abstract.
- Type
- Follow-up of a randomised trial
- Role
- Co-author, author 4 of 7
- Subjects
- haemolytic disease of the fetus and newborn, long-term neurodevelopmental outcome
- PMID
- 26159803
citevan Klink JM, van Veen SJ, Smits-Wintjens VE, Lindenburg IT, Rijken M, Oepkes D, Lopriore E. Immunoglobulins in neonates with rhesus hemolytic disease of the fetus and newborn: long-term outcome in a randomized trial. Fetal Diagn Ther. 2016;39(3):209-213. doi:10.1159/000434718